Mateon Therapeutics Selects IQVIA for Its Randomized, Controlled, Multi-Center Clinical Study to Test OT-101 as a Treatment for COVID-19 Patients

Mateon Therapeutics has selected IQVIA to manage C001, a Phase II randomized, controlled, multi-center clinical study of OT-101.
[Mateon Therapeutics]
Press Release
Bookmark

No account yet? Register

Share

Structural Plasticity of SARS-CoV-2 3CL Mpro Active Site Cavity Revealed by Room Temperature X-Ray Crystallography

Investigators report the room temperature X-ray structure of unliganded SARS-CoV-2 3CL Mpro, revealing the ligand-free structure of the active site and the conformation of the catalytic site cavity at near-physiological temperature.
[Scientific Reports]
Full Article
Bookmark

No account yet? Register

Share

SARS-CoV-2 Infection of the Placenta

Scientists analyzed placenta for the presence of SARS-CoV-2 through molecular and immunohistochemical assays and by and electron microscopy, and measured the maternal antibody response in blood to this infection.
[Journal of Clinical Investigation]
AbstractFull Article
Bookmark

No account yet? Register

Share

It’s a Nightmare.’ How Brazilian Scientists Became Ensnared in Chloroquine Politics

In April, a published study showed chloroquine could increase mortality in COVID-19 patients. Since then, they have been accused of poisoning their patients with a high dose of chloroquine just to give the drug—praised by US President Donald Trump and his Brazilian counterpart Jair Bolsonaro—a bad name.
[ScienceInsider]
Press Release
Bookmark

No account yet? Register

Share

Top US Health Officials Say They Were Never Told to Slow Down COVID-19 Testing, Contradicting Trump

Four key government health care officials said Tuesday that despite recent remarks from President Trump, they were never ordered to “slow down” diagnostic testing for Covid-19.
[STAT News]
Press Release
Bookmark

No account yet? Register

Share

Drug Recently Shown to Reduce Coronavirus Death Risk Could Run Out, Experts Warn

A report that dexamethasone, a commonly used corticosteroid, reduces death rates of COVID-19 by up to one-third was greeted with enthusiasm around the globe. It also raised a question: Will there be enough of the medication?
[ScienceInsider]
Press Release
Bookmark

No account yet? Register

Share

Coronavirus Misinformation, and How Scientists Can Help to Fight It

Scientists are well placed to help to hold back the tide of COVID-19 misinformation — but should they get involved in time-consuming, and sometimes bruising, efforts to do so, or just stick to doing good research?
[Nature News]
Press Release
Bookmark

No account yet? Register

Share

Clinical and Immunological Assessment of Asymptomatic SARS-CoV-2 Infections

Researchers studied 37 asymptomatic individuals in the Wanzhou District who were diagnosed with RT–PCR-confirmed SARS-CoV-2 infections but without any relevant clinical symptoms in the preceding 14 days and during hospitalization.
[Nature Medicine]
Full Article
Bookmark

No account yet? Register

Share

Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike

Researchers found that the monoclonal antibody CR3022 bound the receptor binding domain (RBD) tightly, neutralizing SARS-CoV-2 and report the crystal structure at 2.4 Å of the Fab/RBD complex.
[Cell Host & Microbe]
AbstractFull ArticleGraphical Abstract
Bookmark

No account yet? Register

Share

COVID-19 Revisiting Inflammatory Pathways of Arthritis

The pattern of pro-inflammatory cytokines induced in COVID-19 has similarities to those targeted in the treatment of rheumatoid arthritis. Several clinical studies are underway that test the effects of inhibiting IL-6, IL-1β or TNF or targeting cytokine signaling via Janus kinase inhibition in the treatment of COVID-19.
[Nature Reviews Rheumatology]
Full Article
Bookmark

No account yet? Register

Share

The Vascular Endothelium: The Cornerstone of Organ Dysfunction in Severe SARS-CoV-2 Infection

Venous thrombotic events, particularly pulmonary embolism, with elevated D-dimer and coagulation activation are highly prevalent in COVID-19 patients. The pro-inflammatory cytokine storm, with elevated levels of interleukin-6 (IL-6), IL-2 receptor, and tumor necrosis factor-α, could also participate in endothelial dysfunction and leukocyte recruitment in the microvasculature.
[Critical Care]
[zotpress userid=’6445212 items=’5RTRJKZ4′ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share
Share